The IMF InfoLine team is here to support you and your loved ones with the most up-to-date information about myeloma
Call the IMF InfoLine at 1.800.452.CURE (toll-free in the U.S. & Canada) or 1.818.487.7455 (worldwide), or email InfoLine@myeloma.org with your questions, or if you wish to discuss the contents of this booklet.
Want answers and don’t want to wait?
Get the answers you need anytime from Myelo® , your 24/7 generative AI assistant that is designed to support you living well with myeloma. Ask Myelo your questions at myeloma.org.
Join the Myeloma Knowledge Platform Visit myprofile.myeloma.org and create your online IMF account to receive the most helpful content recommendations tailored to support your personal myeloma experience.
You are not alone
The International Myeloma Foundation (IMF) is here to help you. We are committed to providing information and support for patients with multiple myeloma (which we refer to simply as “myeloma”) and their care partners, friends, and family members.
The IMF supports the myeloma community with a broad range of resources available on our website myeloma.org, and through numerous programs and services such as publications, seminars, webinars, workshops, and the IMF InfoLine.
The IMF InfoLine responds to your myeloma-related questions and concerns in a compassionate and caring manner. To receive the most up-to-date information about myeloma, call 1.818.487.7455, email InfoLine@myeloma.org, or schedule a convenient time to talk with an IMF InfoLine Coordinator at mmsm.link/infoline.
IMF publications
Myeloma is a cancer that is not known to most patients at the time of their diagnosis. If you have been diagnosed with myeloma or if you suspect that you might have myeloma, the IMF can help you become well-informed about this disease so that you can have an active role in your own medical care and make good decisions about your care in partnership with your medical team.
We suggest that you read the IMF’s Patient Handbook, an introductory overview of myeloma diagnosis, risk stratification, effects on the body, as well as treatment options and key supportive care measures approved by the U.S. Food and Drug Administration (FDA). This booklet will also direct you to other resources that may be relevant in your particular case.
The IMF’s Understanding-series publications are intended to offer more detailed information about a broad range of myeloma-specific topics, including drugs and drug regimens, and the symptoms and the side effects of both myeloma and its treatments. All IMF publications are free-of-charge and can be read, downloaded, or requested in printed format at publications.myeloma.org.
Understanding myeloma vocabulary
Words in bold+blue in IMF publications are explained in a companion booklet, Understanding Myeloma Vocabulary. Myeloma is a complicated disease, but the language that describes it doesn’t have to be hard to understand. You can access the electronic edition of this booklet at glossary.myeloma.org.
If you prefer to access any of the IMF’s publications or resources in electronic format, the light blue links will take you there.
What you will learn from this booklet
This booklet discusses a myeloma treatment regimen called Isa-VRd, which is comprised of four drugs: monoclonal antibody Sarclisa® (isatuximab-irfc) + proteasome inhibitor Velcade® (bortezomib) + immunomodulatory agent Revlimid® (lenalidomide) + steroid dexamethasone. You will learn about the indication for the use of Isa-VRd, clinical trials experience with this combination therapy, dose and schedule, safety precautions, and possible common side effects and how to prevent or manage them.
The Isa-VRd regimen combines four FDA-approved drugs, each from a different drug class and with a different way of attacking myeloma. Each drug enhances the activity of the other drugs. For a more comprehensive discussion of each drug that is part of this quadruplet combination, read these IMF publications, listed below in alphabetical order:
¡ Understanding Dexamethasone in the Treatment of Myeloma
¡ Understanding REVLIMID® (lenalidomide)
¡ Understanding SARCLISA® (isatuximab-irfc)
¡ Understanding VELCADE® (bortezomib)
Who is a candidate for Isa-VRd
In September 2024, the U.S. Food and Drug Administration (FDA) approved the use of Isa-VRd for patients with newly diagnosed multiple myeloma (NDMM) who are not eligible (TNE) for autologous stem cell transplant (ASCT).
Treatment of NDMM
The first treatment given to a patient with NDMM is called frontline therapy. The selection of the optimal frontline therapy is very important. Frontline therapy is used in an effort to achieve response or remission, and it has a long-term effect because the patient’s first remission is usually their longest.
Response to treatment refers to a clinically meaningful improvement in the signs and symptoms of myeloma. The term “remission” is used interchangeably with the term “response” to indicate a complete or partial disappearance of the signs and symptoms of myeloma.
An approval by the FDA of a frontline therapy for NDMM typically requires clinical trial data that demonstrates the treatment’s efficacy and safety after comparing it to standard-of-care (SOC) therapy. SOC is a benchmark treatment that is widely accepted by medical experts as the most appropriate to be used in a particular setting.
SOC therapies for patients with myeloma continue to evolve as newer and more effective treatments become available, setting new benchmarks. SOC
may also be called “best practice” or “best available therapy” or “standard therapy.” The goal for new treatment approaches is to increase the rates of response, the depth of response, and to lower the rates of side effects.
Treatment of RRMM
A drug or drug combination is typically first approved by the FDA to be used for patients with relapsed or refractory multiple myeloma (RRMM) before it is approved by the FDA for patients with NDMM. Therapies approved for NDMM generally continue to be available for patients with RRMM.
Patients with relapsed myeloma have been treated, then developed signs and symptoms of myeloma at least 60 days after this treatment ended. Myeloma is considered to be refractory in patients who have had progressive disease either during treatment or within 60 days following treatment.
Quadruplets vs. triplets
Previously, the triplet (3-drug) regimen of Velcade + Revlimid + dexamethasone [ VRd] had been considered the standard-of-care for most patients with NDMM. The other commonly used triplet regimen, primarily in patients with NDMM who are not eligible for ASCT, has been Darzalex® (daratumumab) + Revlimid + dexamethasone [DRd].
The FDA approval of Isa-VRd validates the complex biology of myeloma, which can be better controlled with multiple drugs that have different mechanisms of action (MoA), the process through which a drug induces its effect in the body.
To learn more about the VRd triplet regimen, without the addition of Sarclisa, read the following IMF publication:
¡ Understanding the VRd Regimen for Newly Diagnosed Myeloma
Clinical trial experience with Isa-VRd
A clinical trial is a medical research study with people who volunteer to test scientific approaches for preventing, detecting, diagnosing, or treating cancer, or to answer scientific questions. A clinical trial is launched only after laboratory studies have demonstrated the potential of a treatment or procedure to be more effective and/or less harmful than previously existing methods. The goal of clinical trials is to improve patient care.
The endpoints (goals) used in the clinical trials of quadruplet regimens for NDMM were progression-free survival (PFS) and overall survival (OS). PFS is the length of time during and after the patient’s treatment in which the disease does not get worse. OS is the median number of individuals in a group who are alive after a particular duration of time.
The many advances achieved in the field of myeloma have resulted in the lengthening duration of OS. This is great news for many patients. This also has made OS a difficult endpoint to use in clinical trials as a measure of treatment efficacy, leading to the effort to validate efficacy using minimal residual disease (MRD) as a new endpoint.
Highly sensitive testing methods are now able to detect as little as 1 myeloma cell among 1,000,000 sampled cells in blood or bone marrow. MRD is the presence of residual tumor cells after treatment has been completed and complete response (CR) or stringent complete response (sCR) has been attained. A patient is considered MRD-negative when not even 1 myeloma cell is found in the patient’s sampled bone marrow plasma cells.
Many clinical trials of the Isa-VRd quadruplet regimen have investigated different aspects of this combination therapy. The following are just some of the studies that produced impressive data.
Isa-VRd for patients eligible for ASCT
The GMMG-HD7 clinical trial final analysis presented at the 2024 American Society of Hematology (ASH) annual meeting showed that approximately 66% of patients achieved MRD-negativity with Isa-VRd plus ASCT, while less than half achieved MRD-negativity with the VRd regimen without Sarclisa.
At a median follow-up of 48 months, 18 weeks of Isa-VRd induction therapy – without consolidation therapy – resulted in a 30% reduction in risk of progression or death when compared with VRd, regardless of which maintenance therapy was received by the patient. As of July 2025, the Isa-VRd combination is approved in Europe and is being reviewed for approval in the United States.
Isa-VRd for patients NOT eligible for ASCT
¡
Isa-VRd vs. VRd
The IMROZ clinical trial of Isa-VRd vs. VRd was the basis of the FDA approval of the Isa-VRd regimen. Data presented at the 2024 annual meeting of the American Society of Clinical Oncology (ASCO) demonstrated impressive improvement in PFS. This study evaluated 446 patients who were 80 years of age or younger.
An independent review committee assessed PFS efficacy using criteria by the IMF International Myeloma Working Group (IMWG). The median PFS (mPFS) was not reached in the Isa-VRd arm of the study; it was 54.3 months in the VRd arm. In the Isa-VRd arm, 63% of study patients were still in remission at 4 years vs. 45% of patients in the VRd arm.
¡ Isa-VRd vs. Isa-Rd
The BENEFIT clinical trial of Isa-VRd vs. Isa-Rd demonstrated that at all time points in this study, patients receiving Isa-VRd achieved better
response rates, with superior rates of MRD and sustained MRD (sMRD, which demonstrated better correlation to survival times than a onetime measurement of the best MRD rate). Data was presented at the 2025 ASH annual meeting.
The number of patients who relapsed within 24 months is lower with Isa-VRd than with Isa-Rd. The Isa-VRd quadruplet regimen was well tolerated, with a safety profile consistent with the individual agents. Velcade was given once-weekly for 18 months.
VRd-lite
The “VRd-lite” approach was used for patients in both IMROZ and BENEFIT clinical trials, with less frequent administration of Velcade (which was given once-weekly instead of twice-weekly), lower doses of Revlimid, and more rapid dose-tapering of dexamethasone.
Both IMROZ and BENEFIT studies demonstrate that for patients under the age of 80 who do not intend to proceed to transplant, the VRd-lite approach is both feasible and effective, with deep and durable responses.
Sarclisa on-body delivery system
Two clinical trials – IRAKLIA and IZALCO – are investigating the administration of Sarclisa with an on-body delivery system (OBDS), a wearable bolus injector that allows for subcutaneous (SQ) injection of the medication. This method would offer a shorter administration time and would minimize the time a patient spends in clinic. OBDS is not yet approved by the FDA.
Finding a study to match your needs
Participating in a clinical trial may give you access to treatment that is not yet available outside of a study. If you have an interest in participating in a clinical trial, be sure to discuss with the doctor treating your myeloma all the potential risks and benefits that may apply to your particular case.
Clinical research in myeloma has become a robust field, with many studies enrolling patients at any given time. To help myeloma patients with personalized support for identifying and exploring clinical trial options across the U.S., the IMF has partnered with SparkCures. Visit myeloma.org/sparkcures or contact the IMF InfoLine for more information.
The U.S. government maintains the website clinicaltrials.gov, an online database of thousands of research studies from around the world. You may wish to also explore this resource. However, the U.S. government does not review or approve the safety and science of all the studies listed on this website.
For more information about what’s involved in study participation, read the IMF’s publication Understanding Clinical Trials in Myeloma.
Dose and schedule for ASCT-eligible patients
The information below is based on the Isa-VRd study arm of the GMMG-HD7 clinical trial. Your myeloma doctor may modify your dose and schedule based on factors applicable to your particular case.
Induction therapy (3 Cycles of 6 weeks each)
¡ Sarclisa is given as an intravenous (IV) infusion. The recommended dose is 10 mg/kg. Patients are pre-medicated with dexamethasone, acetaminophen, an H2 antagonist, and diphenhydramine. Based on standard guidelines, you may be given an antibacterial and/or an antiviral medication. No post-infusion medication is needed.
In Cycle 1, Sarclisa is given once-weekly for a total of 5 doses on days 1, 8, 15, 22, and 29. Infusion duration can be decreased over time.
• The duration of the first infusion is 3 hours and 20 minutes.
• The second infusion is 1 hour and 53 minutes.
• The third infusion and beyond is 75 minutes each.
In Cycles 2 and 3, Sarclisa is given every two weeks for a total of 3 doses on days 1, 15, and 29. Infusions are 75 minutes each.
¡ Velcade can be given as an SQ injection at a dose of 1.3 mg/m2 (milligram per square meter of body mass) on days 1, 4, 8, 11, 22, 25, 29, and 32 of each Cycle. Data show that Velcade can retain full efficacy while significantly reducing the risk of side effects when given once-weekly instead of twice-weekly and/or at a lower dose. SQ injections of Velcade should be given using a sequential rotation of four sites: the left and right sides of the abdomen and the left and right thighs. There are no data to support SQ injections given in the arm.
¡ Revlimid is a capsule taken orally with water at a starting dose of 25 mg per day on days 1 through 14 and 22 through 35 of each Cycle. Your doctor may reduce your dose to 20 mg, then to 15 mg, then to 10 mg, and even to 5 mg or 2.5 mg if appropriate in your particular case.
¡ Dexamethasone can be taken either as an oral pill with/after a meal or as an IV infusion at a starting dose of 20 mg on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 22, 23, 29, 30, 32, and 33 of each Cycle. Several clinical trials have proven that dexamethasone can be effective at doses as low as 4 mg given once-weekly while reducing or eliminating potential side effects. In addition, emerging evidence demonstrates that dexamethasone can be tapered down as soon as after 2 Cycles and even discontinued as soon as after 6 Cycles. Discuss with your doctor if this might be appropriate for your specific case of myeloma.
Transplant
The medical term for an autologous stem cell transplant (ASCT) is “high-dose therapy (HDT) with stem cell rescue.” ASCT has been used as a treatment for myeloma for several decades. In patients with myeloma, the cancer cells are intermixed in the same bone marrow microenvironment as the normal stem cells from which all blood cells develop. HDT is more effective at killing myeloma cells in the bone marrow than standard-dose chemotherapy, but HDT is also capable of damaging your normal stem cells. In the ASCT procedure, your stem cells are harvested (collected) before HDT is administered, then reinfused (transplanted) into the patient to “rescue” the bone marrow from the effects of HDT. For more information, read the IMF’s publication Understanding Stem Cell Transplant in Myeloma.
Maintenance therapy (4-week Cycles)
Depending upon response and tolerability, maintenance therapy Cycles are repeated for up to a maximum of 3 years or until progressive disease.
¡ Sarclisa is given as an IV infusion at the recommended dose of 10 mg/kg.
In Cycle 1, Sarclisa is given every week for a total of 4 doses on days 1, 8, 15, and 22.
In Cycles 2 and 3, Sarclisa is given every two weeks for a total of 2 doses on days 1 and 15.
In Cycles 4 and beyond, one dose of Sarclisa is given on day 1 of each Cycle.
¡ Revlimid is taken at the dose of 10 mg on days 1 through 28 of each Cycle. The dose is increased to 15 mg after 3 months.
¡ Dexamethasone is given on days 1, 8, 15, and 22 of each Cycle.
Dose and schedule for ASCT-ineligible patients
The information below is based on the Isa-VRd study arm of the IMROZ clinical trial. Your myeloma doctor may modify your dose and schedule based on factors applicable to your particular case.
Frontline therapy (4 Cycles of 6 weeks each)
¡ Sarclisa is given as an IV infusion. The recommended dose is 10 mg/kg. Patients are pre-medicated with dexamethasone, acetaminophen, an H2 antagonist, and diphenhydramine. An antibacterial and/or an antiviral medication may be given based on standard guidelines. No post-infusion medication is needed.
In Cycle 1, Sarclisa is given once-weekly for a total of 5 doses on days 1, 8, 15, 22, and 29. Infusion duration can be decreased over time.
• The duration of the first infusion is 3 hours and 20 minutes.
• The second infusion is 1 hour and 53 minutes.
• The third infusion and beyond is 75 minutes each.
In Cycles 2–4, Sarclisa is given every two weeks for a total of 3 doses on days 1, 15, and 29. Infusions are 75 minutes each.
¡ Velcade SQ is given at a dose of 1.3 mg/m2 (milligram per square meter of body mass) as an SQ injection on days 1, 4, 8, and 11 of each Cycle. Data show that Velcade can retain full efficacy while significantly reducing the risk of side effects when given once-weekly instead of twice-weekly and/or at a lower dose. SQ injections of Velcade should be given using a sequential rotation of four sites: the left and right sides of the abdomen and the left and right thighs. There are no data to support SQ injections given in the arm.
¡ Revlimid is a capsule taken orally with water at a starting dose of 25 mg per day on days 1 through 14 and 22 through 35 of each Cycle. Your doctor may reduce your dose to 20 mg, then to 15 mg, then to 10 mg, and even to 5 mg or 2.5 mg if appropriate in your particular case.
¡ Dexamethasone can be taken either as an oral pill with/after a meal or as an IV infusion at a starting dose of 20 mg on days 1, 2, 8, 9, 15, and 16 of each Cycle. Several clinical trials have proven that dexamethasone can be effective at doses as low as 4 mg given once-weekly while reducing or eliminating potential side effects. In addition, emerging evidence demonstrates that dexamethasone can be tapered down as soon as after 2 Cycles and even discontinued as soon as after 6 Cycles. Discuss with your doctor if this might be appropriate for your specific case of myeloma.
Continuous therapy (4-week Cycles)
¡ Sarclisa is given as an IV infusion at the recommended dose of 10 mg/kg.
In Cycle 5–17, Sarclisa is given every two weeks for a total of 2 doses on days 1 and 15.
In Cycles 18 and beyond, one dose of Sarclisa is given on day 1 of each Cycle.
¡ Revlimid is taken on days 1 through 21 of each Cycle.
¡ Dexamethasone is given on days 1, 8, 15, and 22 of each Cycle.
Monitoring
Your doctor may order blood tests or imaging studies before or during your course of treatment for reasons that include the following:
¡ To monitor your response to quadruplet therapy,
¡ To manage possible side effects,
¡ To promptly detect possible disease progression,
¡ To determine if it is most appropriate to continue with treatment as planned or to modify the dose/schedule of future Cycles, to delay treatment while addressing a side effect, or to begin a different treatment regimen.
Safety precautions
A side effect is an unwanted or unexpected effect caused by a drug, sometimes called an adverse event (AE). Safety precautions must be exercised with the use of all myeloma therapies. You will be monitored frequently. Dose reductions and interruptions may be required. Your doctor will discontinue treatment for life-threatening reactions.
Infusion-related reaction (IRR)
Infusion-related reactions, including life-threatening reactions, have occurred with Sarclisa treatment in less than 1% of patients who participated in the ICARIA-MM, IKEMA, and IMROZ clinical trials. Signs and symptoms include cardiac arrest, hypertension, hypotension, bronchospasm, dyspnea, angioedema, and swelling.
IRR can occur with many IV-administered cancer therapies. IRR is caused by cytokines, small proteins released from cells targeted by the monoclonal antibody in order to affect the behavior of other cells, and also from immune cells that are recruited to the area. Reactions are often flu-like, and include nasal congestion, fever, chills, cough, throat irritation, shortness of breath, low blood pressure, nausea, and rash.
Prevention and treatment of IRR
Medication will be prescribed to decrease the risk and severity of IRRs. Medications may include acetaminophen, H2 antagonists, diphenhydramine or equivalent, and/or dexamethasone. If an IRR occurs, the infusion may be stopped.
Infections
Infections can be severe, life-threatening, or fatal. Medication will be prescribed to decrease the risk and severity of infections. In the abovecited clinical trials, serious infections occurred in 46% of study patients who received Sarclisa at the recommended dose, Grade 3 or 4 infections occurred in 43%, and fatal infections occurred in 4.7%. The most common serious infection reported was pneumonia, which occurred in 32% of study patients. Immediately contact your doctor if you experience any signs or symptoms of infection, including fever, shortness of breath, sore throat, flu-like symptoms (body aches, sweating, chills), cough, or chest pain when you breathe or cough.
Prevention and treatment of infection
To decrease the risk and severity of infections, you may be given prophylactic medication in accordance with guidelines. You must report any signs or symptoms of infection to your doctor, who will determine how they should be managed.
Neutropenia
Neutropenia is a reduced level of a type of white blood cell (WBC) called neutrophils. Neutropenia can lead to infection caused by bacteria or fungi. Neutropenia occurred in 81% of patients who received Sarclisa in the abovecited clinical trials, with Grade 3 or 4 in 52% of study patients. Fever is the most common sign of neutropenia. If you develop a fever, you must get immediate medical attention.
Prevention and treatment of neutropenia
Your neutrophil count will be monitored while you receive treatment with Sarclisa. If your doctor determines that the level of your neutrophils is low, your doses of Sarclisa may be decreased or interrupted. You may also receive a colony-stimulating factor (CSF) to increase your WBC production.
Second primary malignancy (SPM)
SPM occurred in 12% of clinical trial patients treated with Sarclisa. The most common SPMs that occurred in 1% or more of study patients included skin cancers and solid tumors (other than skin cancers).
Laboratory test interference
The use of Sarclisa may interfere with the following laboratory tests:
¡ Sarclisa may interfere with serological (blood) testing. Patients are tested for blood type before their first infusion of Sarclisa. Interference with blood compatibility testing can be resolved using dithiothreitoltreated RBCs. If an emergency transfusion is required, non-crossmatched ABO/RhD-compatible RBCs can be given as per local blood bank practices.
¡ Sarclisa may have an impact on the accuracy of serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE) laboratory tests used to monitor monoclonal protein (myeloma protein, M-protein). This can impact the accuracy of the determination of complete response (CR) in some patients with IgG kappa myeloma protein.
Embryo-fetal toxicity
Sarclisa can cause fetal harm. Females of reproductive potential and males with female partners of reproductive potential should ask their treating doctor if the use of effective contraception is necessary before treatment
begins, during treatment, or for a period of time after the last dose of treatment is administered. Due to the potential for harm in the breastfed child, lactating women should not breastfeed during treatment with Isa-VRd.
Possible common side effects
Anemia (low red blood cell count)
Red blood cells contain hemoglobin, a protein that carries oxygen to the body’s tissues and organs. Anemia is usually defined as a decrease in hemoglobin < 10 g/dL or as a decrease of ≥ 2 g/dL from the normal level for an individual. More than 13–14 g/dL is considered normal. Low levels of oxygen in the body may cause shortness of breath and feelings of exhaustion.
Prevention and treatment of anemia
Your healthcare providers will determine which treatment regimen for anemia is best suited to your needs and safest for you. The following are options for treatment of anemia:
¡ Adjusting medications.
¡ Blood transfusions.
¡ Erythropoietic (red blood cell-making) agents.
Diarrhea
Diarrhea is defined as 3 or more loose stools per day. Severe diarrhea is defined as 7 or more loose stools per day requiring treatment with IV fluids or hospitalization.
Prevention and treatment of diarrhea
Diarrhea might occur while taking Sarclisa, causing dehydration. Precautions should be taken to prevent dehydration caused by either excessive or persistent diarrhea. Be sure to drink a sufficient amount of water. Contact your doctor if you experience dizziness, light-headedness, and/or fainting. Your doctor may administer medication or IV hydration.
Fatigue
Fatigue caused by cancer or cancer treatment is a distressing, persistent, subjective sense of tiredness or exhaustion that is not proportional to recent activity and interferes with usual functioning. Fatigue that is related to cancer and its treatments is different from – and more severe than – normal fatigue. It tends to last longer, and includes the feeling of overall weakness.
Prevention and treatment of fatigue
The effects of fatigue may be minimized by maintaining the following:
¡ A moderate level of activity,
¡ A healthy diet and proper fluid intake,
¡ A consistent sleeping schedule,
¡ Regularly scheduled visits with your doctor to monitor your red blood cell count (low red blood cells, or anemia, can cause fatigue) and to discuss issues that may contribute to your fatigue, and
¡ A careful review of the side effects of any other medications you are taking to ensure that they are not contributing to your fatigue.
For more information about this side effect, read the IMF’s publication Understanding Fatigue.
Hypertension
Hypertension (HTN) is a medical condition in which the blood pressure (BP) in the arteries is elevated; also known as high blood pressure (HBP).
Prevention and treatment of hypertension
If you have HTN prior to starting treatment with Kyprolis, your doctor should optimize treatment of your HTN in advance. Monitor BP carefully when receiving your myeloma therapy, especially during the first month. If very high BP or complications develop, report this to your doctor immediately. Your doctor will determine if your medication should be reduced, interrupted, or discontinued.
Other possible common side effects reported in clinical trials of Sarclisa include thrombocytopenia (low number of platelets), upper respiratory tract infection, trouble sleeping, back pain, peripheral neuropathy, muscle or bone pain, cataract, constipation, rash, COVID-19, and swelling of the hands, legs, ankles and feet. For more information, read the IMF’s publication Understanding SARCLISA® (isatuximab-irfc).
Access and support
If you and your doctor have decided that the Isa-VRd regimen is appropriate for the treatment of your myeloma, you can choose to enroll in the “CareASSIST” program for personalized assistance with a variety of resources, including potential cost support options. Visit sarclisa.com/paying-for-sarclisa for more information.
In closing
This booklet is not meant to replace the advice of your doctors and nurses who are best able to answer questions about your specific healthcare management plan. The IMF intends only to provide you with information that will guide you in discussions with your healthcare team.
To help ensure a good quality of life through effective treatment, you must play an active role in your own medical care. We encourage you to visit
myeloma.org for more information and to join the Myeloma Knowledge Platform at myprofile.myeloma.org.
To receive the most up-to-date information about myeloma in a caring and compassionate manner, call the IMF InfoLine at 1.818.487.7455, email InfoLine@myeloma.org, or visit mmsm.link/infoline to schedule a convenient time to talk with an IMF InfoLine Coordinator.
To get answers to your questions without having to wait, ask Myelo® anytime 24/7 at myeloma.org. This generative AI assistant is designed to help you find the right resources.
Use the hyperlinks and web addresses included in this publication for quick access to a variety of resources. Sign up at subscribe.myeloma.org for our quarterly journal Myeloma Today and weekly e-newsletter Myeloma Today, as well as alerts about IMF news, events, and actions.
Founded in 1990, the International Myeloma Foundation (IMF) is the world’s leading organization dedicated to multiple myeloma. The IMF is steadfast in its mission to improve the quality of life of myeloma patients while working toward prevention and a cure. The IMF serves people affected by myeloma at every stage of the disease.
The IMF combines world-class research, trusted education, global advocacy, and direct support. A cornerstone of this work is the IMF International Myeloma Working Group® (IMWG®), comprised of more than 350 renowned researchers and clinicians who establish the guidelines that shape how myeloma is diagnosed, treated, and managed worldwide.
The IMF ensures that scientific advances translate into better care and outcomes. Through the IMF InfoLine, educational programs, a global network of support groups, the 24/7 generative-AI myeloma assistant Myelo®, and our advocacy for healthcare access, the IMF helps people living with myeloma and their care partners navigate diagnosis and survivorship.
The IMF is driven by its vision of a world where every myeloma patient can live life to the fullest, unburdened by the disease.